81090 Federal Register / Vol. 89, No. 194 / Monday, October 7, 2024 / Notices 

Technology Transfer Center, 9609 

Medical Center Drive, RM 3W–204, 

MSC 9702, Bethesda, MD 20892–9702 

(for business mail), Rockville, MD 

20850–9702; Telephone: (240)–276– 

5530; Email: suna.gulay@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

1. United States Provisional Patent 

Application No. 62/327,529, filed April 

26, 2016 and entitled ‘‘Anti-KK–LC–1 T 

Cell Receptors’’ [HHS Reference No. E– 

153–2016–0–US–01]; 

2. PCT Patent Application No. PCT/ 

US2017/027865, filed April 17, 2017 

and entitled ‘‘Anti-KK–LC–1 T Cell 

Receptors’’ [HHS Reference No. E–153– 

2016–0–PCT–02]; 

3. Australian Patent No. 2017258745, 

issued July 14, 2022 and entitled ‘‘AntiKK–LC–1 T Cell Receptors’’ [HHS 

Reference No. E–153–2016–0–AU–03]; 

4. Canadian Patent Application No. 

3021898, filed April 17, 2017 and 

entitled ‘‘Anti-KK–LC–1 T Cell 

Receptors’’ [HHS Reference No. E–153– 

2016–0–CA–04]; 

5. European Patent No. 3448882, 

issued November 24, 2021 and entitled 

‘‘Anti-KK–LC–1 T Cell Receptors’’ [HHS 

Reference No. E–153–2016–0–EP–05]; 

a. Validated in the following 

jurisdictions: CH, DE, BE, DK, ES, FI, 

FR, GB, IE, IT, NL, NO and SE. 

6. U.S. Patent No. 11,352,410, issued 

June 7, 2022 and entitled ‘‘Anti-KK–LC– 

1 T Cell Receptors’’ [HHS Reference No. 

E–153–2016–0–US–06]. 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to the 

following: 

‘‘1. Development, manufacture, and 

commercialization of autologous T cell 

therapy products, including T cells with 

stem-like properties, engineered via 

retrovirus-mediated gene transfer to 

express T cell receptors reactive to KitaKyushu Lung Cancer Antigen 1 (KK– 

LC–1), as claimed in the Licensed Patent 

Rights; such products to be developed 

for treatment of patients carrying HLA– 

A*01:01 histocompatibility haplotype, 

and diagnosed with a cancer expressing 

KK–LC–1 protein (‘‘KK–LC–1 Targeting 

TCR–T Products’’). 

2. Development, manufacture, and 

commercialization of a combination 

therapy for the treatment of KK–LC–1 

expressing human cancers, independent 

of their HLA phenotype, wherein the 

treatment comprises: 

a. Modification of the patient’s tumor 

using Licensee’s proprietary technology 

to express the HLA–A*01:01 restriction 

element, and 

b. Treatment with the KK–LC–1 

Targeting TCR–T Products. 

For the avoidance of doubt, 

specifically excluded from these Fields 

of Use are Natural Killer cell therapy 

products engineered via viral vectors 

(including lentivirus or retrovirus) to 

express the TCR(s) claimed in the 

Licensed Patent Rights.’’ 

This technology discloses isolated T 

cell receptors (TCR) reactive to the KitaKyushu lung cancer antigen 1 (KK–LC– 

1) within the context of human 

leukocyte antigen (HLA) A*01:01. KK– 

LC–1 is expressed by various epithelial 

cancers including carcinomas of the 

bladder, cervix, stomach, breast, lung, 

and pancreas. Due to its minimal 

expression in normal tissues, this 

antigen may be targeted on KK–LC–1- 

expressing tumors with minimal normal 

tissue toxicity. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: October 1, 2024. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2024–23029 Filed 10–4–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Biological Chemistry 

and Macromolecular Biophysics Integrated 

Review Group; Drug Discovery and 

Molecular Pharmacology B Study Section. 

Date: October 31-November 1, 2024. 

Time: 8:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Razvan Cornea, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 904L, 

Bethesda, MD 20892, (301) 480–1955, 

cornearl@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Imaging and 

Bioengineering Technology for Visual 

Systems (IBV). 

Date: November 4–5, 2024. 

Time: 8:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate, 2650 Virginia 

Avenue NW, Washington, DC 20037. 

Contact Person: Susan Gillmor, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (240) 762–3076, susan.gillmor@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Learning, Memory, Language, 

Communication and Related Neuroscience. 

Date: November 4–5, 2024. 

Time: 8:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Canopy by Hilton, 940 Rose Avenue, 

North Bethesda, MD 20852. 

Contact Person: Alexei Kondratyev, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5200, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1785 kondratyevad@csr.nih.gov. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 194 / Monday, October 7, 2024 / Notices 81091 

Name of Committee: Applied Therapeutics 

for Cancer Integrated Review Group; Drug 

Discovery and Molecular Pharmacology C 

Study Section. 

Date: November 4–5, 2024. 

Time: 8:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Westin Georgetown, 2350 M 

Street NW, Washington, DC 20037. 

Contact Person: Jeffrey Smiley, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6194, 

MSC 7804, Bethesda, MD 20892, (301) 272– 

4596, smileyja@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Radiation Therapeutics and Biology. 

Date: November 4, 2024. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Lambratu Rahman Sesay, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6214, 

MSC 7804, Bethesda, MD 20892, 301–905– 

8294, rahman-sesay@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

conflict: Topics on Biobehavioral Processes 

Date: November 4–5, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Natalie S Dailey, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 827–4451, daileyns@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–24– 

129: Specific Pathogen Free Macaque 

Colonies. 

Date: November 4, 2024. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Latha Malaiyandi, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 812Q, 

Bethesda, MD 20892, (301) 435–1999, 

malaiyandilm@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 1, 2024. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–23037 Filed 10–4–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID FEMA–2024–0002; Internal 

Agency Docket No. FEMA–B–2463] 

Proposed Flood Hazard 

Determinations 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: Notice. 

SUMMARY: Comments are requested on 

proposed flood hazard determinations, 

which may include additions or 

modifications of any Base Flood 

Elevation (BFE), base flood depth, 

Special Flood Hazard Area (SFHA) 

boundary or zone designation, or 

regulatory floodway on the Flood 

Insurance Rate Maps (FIRMs), and 

where applicable, in the supporting 

Flood Insurance Study (FIS) reports for 

the communities listed in the table 

below. The purpose of this notice is to 

seek general information and comment 

regarding the preliminary FIRM, and 

where applicable, the FIS report that the 

Federal Emergency Management Agency 

(FEMA) has provided to the affected 

communities. The FIRM and FIS report 

are the basis of the floodplain 

management measures that the 

community is required either to adopt 

or to show evidence of having in effect 

in order to qualify or remain qualified 

for participation in the National Flood 

Insurance Program (NFIP). 

DATES: Comments are to be submitted 

on or before January 6, 2025. 

ADDRESSES: The Preliminary FIRM, and 

where applicable, the FIS report for 

each community are available for 

inspection at both the online location 

https://hazards.fema.gov/femaportal/ 

prelimdownload and the respective 

Community Map Repository address 

listed in the tables below. Additionally, 

the current effective FIRM and FIS 

report for each community are 

accessible online through the FEMA 

Map Service Center at https://

msc.fema.gov for comparison. 

You may submit comments, identified 

by Docket No. FEMA–B–2463, to Rick 

Sacbibit, Chief, Engineering Services 

Branch, Federal Insurance and 

Mitigation Administration, FEMA, 400 

C Street SW, Washington, DC 20472, 

(202) 646–7659, or (email) 

patrick.sacbibit@fema.dhs.gov. 

FOR FURTHER INFORMATION CONTACT: Rick 

Sacbibit, Chief, Engineering Services 

Branch, Federal Insurance and 

Mitigation Administration, FEMA, 400 

C Street SW, Washington, DC 20472, 

(202) 646–7659, or (email) 

patrick.sacbibit@fema.dhs.gov; or visit 

the FEMA Mapping and Insurance 

eXchange (FMIX) online at https://

www.floodmaps.fema.gov/fhm/fmx_

main.html. 

SUPPLEMENTARY INFORMATION: FEMA 

proposes to make flood hazard 

determinations for each community 

listed below, in accordance with section 

110 of the Flood Disaster Protection Act 

of 1973, 42 U.S.C. 4104, and 44 CFR 

67.4(a). 

These proposed flood hazard 

determinations, together with the 

floodplain management criteria required 

by 44 CFR 60.3, are the minimum that 

are required. They should not be 

construed to mean that the community 

must change any existing ordinances 

that are more stringent in their 

floodplain management requirements. 

The community may at any time enact 

stricter requirements of its own or 

pursuant to policies established by other 

Federal, State, or regional entities. 

These flood hazard determinations are 

used to meet the floodplain 

management requirements of the NFIP. 

The communities affected by the 

flood hazard determinations are 

provided in the tables below. Any 

request for reconsideration of the 

revised flood hazard information shown 

on the Preliminary FIRM and FIS report 

that satisfies the data requirements 

outlined in 44 CFR 67.6(b) is considered 

an appeal. Comments unrelated to the 

flood hazard determinations also will be 

considered before the FIRM and FIS 

report become effective. 

Use of a Scientific Resolution Panel 

(SRP) is available to communities in 

support of the appeal resolution 

process. SRPs are independent panels of 

experts in hydrology, hydraulics, and 

other pertinent sciences established to 

review conflicting scientific and 

technical data and provide 

recommendations for resolution. Use of 

the SRP only may be exercised after 

FEMA and local communities have been 

engaged in a collaborative consultation 

process for at least 60 days without a 

mutually acceptable resolution of an 

appeal. Additional information 

regarding the SRP process can be found 


lotter on DSK11XQN23PROD with NOTICES1